Observational studyMedicine2025
The analysis of risk factors associated with readmission in patients with exacerbation of COPD.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated multi-omics identifies CRP as a prognostic biomarker and reveals complement consumption in HIV-associated AECOPD.Frontiers in immunology · 2026Article
- Association Between Serum Growth Factors and Risk of Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A One-Year Prospective Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate risk factors for readmission within 6 months after acute exacerbation of chronic obstructive pulmonary disease (COPD) and to develop a multifactorial predictive model. A total of 151 patients with acute exacerbation of COPD, admitted to our hospital from October 2021 to December 2023, were included in this retrospective analysis. Data on baseline characteristics, medical history, lung function, lifestyle, comorbidities, inflammatory markers, and treatment adherence were obtained from electronic medical records to identify risk factors associated with readmission. Univariate and multivariate logistic regression analyses were used to identify independent risk factors, construct a predictive model, and assess its predictive efficacy using the receiver operating characteristic (ROC) curve. Patients in the readmission group were older (69.8 ± 9.5 years vs 65.2 ± 8.4 years, P = .048), had a higher proportion of males (76.4% vs 59.5%, P = .032), higher body mass index (25.3 ± 3.8 kg/m2 vs 23.1 ± 3.2 kg/m2, P = .018), more frequent exacerbations (3.2 ± 1.0 episodes vs 1.5 ± 0.8 episodes, P = .009), longer disease duration (12.1 ± 7.3 years vs 8.4 ± 5.7 years, P = .043), and higher GOLD classification (70% in stages III-IV vs 50%, P = .043) and BODE index (5.1 ± 1.4 vs 3.8 ± 1.2, P = .022). Additionally, they had a higher prevalence of cardiovascular comorbidities (55.6% vs 31.6%, P = .015), lower FEV1 levels (45.3 ± 10.1% vs 52.7 ± 8.5%, P = .033), higher levels of C-reactive protein (CRP) (15.2 ± 6.5 mg/L vs 10.4 ± 4.9 mg/L, P = .005), fractional exhaled nitric oxide (FeNO) (32.5 ± 10.4 ppb vs 26.7 ± 8.9 ppb, P = .03), and end-tidal carbon dioxide partial pressure (PetCO2) (40.1 ± 6.3 mm Hg vs 36.2 ± 5.7 mm Hg, P = .028), all of which were significant independent risk factors for readmission. The area under the ROC curve for the multivariate regression model was 0.801, indicating good predictive efficacy. This study evaluates multiple factors affecting readmission risk after acute exacerbation of COPD, highlighting the importance of early identification of high-risk patients and constructing an effective predictive model. Further large-sample, multi-center studies are needed to validate these findings and explore personalized interventions to reduce readmission rates and improve the quality of life for COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.